Request a Rep
In QUAZAR® AML-001, the pivotal, randomized, double-blind, phase III study, ONUREG demonstrated a statistically significant improvement vs placebo in median OS: 24.7 months (95% CI: 18.7, 30.5) vs 14.8 months (95% CI: 11.7, 17.6) , respectively (HR: 0.69 [95% CI: 0.55, 0.86; P=0.0009]).1
Median overall survival was >2 years in patients with acute myeloid leukemia treated with ONUREG
QUAZAR AML-001: select baseline demographic and disease-related characteristics1,4
Across select subgroups in QUAZAR AML-001
In a subgroup analysis of RFS in patients with a CR at randomization in QUAZAR AML-001
In an exploratory analysis of QUAZAR AML-001
At baseline, all patients reported generally favorable levels of HRQoL and fatigue5,7
No clinically meaningful decline in QoL measures was observed in ONUREG or placebo across visits5,7
Would you prescribe ONUREG in a patient like Denise?
Reasons for choosing ONUREG